Cover Image
市場調查報告書

人工胰臟:開發中產品分析

Artificial Pancreas - Medical Devices Pipeline Assessment, 2017

出版商 GlobalData 商品編碼 334921
出版日期 內容資訊 英文 124 Pages
訂單完成後即時交付
價格
Back to Top
人工胰臟:開發中產品分析 Artificial Pancreas - Medical Devices Pipeline Assessment, 2017
出版日期: 2017年08月01日 內容資訊: 英文 124 Pages
簡介

本報告提供目前開發中的人工胰臟的開發中產品資訊調查分析,提供您主要產品·計劃,主要企業,臨床實驗資訊,最近的趨勢等相關的系統性資訊。

第1章 目錄

第2章 簡介

  • 人工胰臟概要

第3章 開發中的產品

  • 人工胰臟 - 開發中產品:各開發階段
  • 人工胰臟 - 開發中產品:各地區
  • 人工胰臟 - 開發中產品:各法規途徑
  • 人工胰臟 - 開發中產品:各核準時期 (預定)
  • 人工胰臟 - 進行中的臨床實驗

第4章 人工胰臟:正在開發的開發中產品 (各企業)

  • 人工胰臟企業 - 開發中產品:各開發階段
  • 人工胰臟 - 開發中產品:各開發階段

第5章 人工胰臟企業與產品概要

  • Advanced Biosensors-Ohio, Llc
  • Animas Corporation
  • Beta-O2 Technologies Ltd.
  • Bigfoot Biomedical, Inc.
  • BioTex, Inc.
  • Boston University
  • Cerco Medical
  • Converge Biotech, Inc.
  • Covalor Medical, LLC
  • De Montfort University
  • Defymed
  • Diabeloop
  • Dose Safety Inc.
  • Imperial College London
  • Inreda Diabetic BV
  • Kencak LLC
  • Medtronic plc
  • Miromatrix Medical Inc.
  • Pacific Diabetes Technologies, Inc.
  • Pancreum, LLC
  • PharmaCyte Biotech, Inc.
  • Rensselaer Polytechnic Institute
  • Schneider Children's Medical Center of Israel
  • TecMed, Inc.
  • The University of Newcastle
  • Ultradian Diagnostics LLC
  • Universidad Autonoma de Madrid
  • Universitat Politecnica de Valencia
  • University of California, San Francisco
  • University of California, Santa Barbara
  • University of Cambridge
  • University of Florida
  • University of Virginia
  • ViaCyte, Inc.
  • XERIS Pharmaceuticals, Inc.

第6章 人工胰臟:最近的趨勢

第7章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDME0399EPD

GlobalData's Medical Devices sector report, "Artificial Pancreas - Medical Devices Pipeline Assessment, 2017" provides an overview of Artificial Pancreas currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Artificial Pancreas pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Artificial Pancreas under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Artificial Pancreas and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Artificial Pancreas under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 5
  • 1.2 List of Figures 8

2 Introduction 9

  • 2.1 Artificial Pancreas Overview 9

3 Products under Development 10

  • 3.1 Artificial Pancreas - Pipeline Products by Stage of Development 10
  • 3.2 Artificial Pancreas - Pipeline Products by Territory 11
  • 3.3 Artificial Pancreas - Pipeline Products by Regulatory Path 12
  • 3.4 Artificial Pancreas - Pipeline Products by Estimated Approval Date 13
  • 3.5 Artificial Pancreas - Ongoing Clinical Trials 14

4 Artificial Pancreas - Pipeline Products under Development by Companies 15

  • 4.1 Artificial Pancreas Companies - Pipeline Products by Stage of Development 15
  • 4.2 Artificial Pancreas - Pipeline Products by Stage of Development 17

5 Artificial Pancreas Companies and Product Overview 19

  • 5.1 Admetsys Corporation Company Overview 19
    • 5.1.1 Admetsys Corporation Pipeline Products & Ongoing Clinical Trials Overview 19
  • 5.2 Advanced Biosensors-Ohio, Llc Company Overview 20
    • 5.2.1 Advanced Biosensors-Ohio, Llc Pipeline Products & Ongoing Clinical Trials Overview 20
  • 5.3 Animas Corp Company Overview 21
    • 5.3.1 Animas Corp Pipeline Products & Ongoing Clinical Trials Overview 21
  • 5.4 Beta Bionics Inc Company Overview 22
    • 5.4.1 Beta Bionics Inc Pipeline Products & Ongoing Clinical Trials Overview 22
  • 5.5 Beta-O2 Technologies Ltd Company Overview 25
    • 5.5.1 Beta-O2 Technologies Ltd Pipeline Products & Ongoing Clinical Trials Overview 25
  • 5.6 Bigfoot Biomedical, Inc. Company Overview 28
    • 5.6.1 Bigfoot Biomedical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 28
  • 5.7 BioTex Inc Company Overview 29
    • 5.7.1 BioTex Inc Pipeline Products & Ongoing Clinical Trials Overview 29
  • 5.8 Cerco Medical LLC Company Overview 30
    • 5.8.1 Cerco Medical LLC Pipeline Products & Ongoing Clinical Trials Overview 30
  • 5.9 Converge Biotech, Inc. Company Overview 31
    • 5.9.1 Converge Biotech, Inc. Pipeline Products & Ongoing Clinical Trials Overview 31
  • 5.10 Covalor Medical, LLC Company Overview 32
    • 5.10.1 Covalor Medical, LLC Pipeline Products & Ongoing Clinical Trials Overview 32
  • 5.11 De Montfort University Company Overview 33
    • 5.11.1 De Montfort University Pipeline Products & Ongoing Clinical Trials Overview 33
  • 5.12 Debiotech SA Company Overview 34
    • 5.12.1 Debiotech SA Pipeline Products & Ongoing Clinical Trials Overview 34
  • 5.13 Defymed Inc Company Overview 35
    • 5.13.1 Defymed Inc Pipeline Products & Ongoing Clinical Trials Overview 35
  • 5.14 Diabeloop Company Overview 36
    • 5.14.1 Diabeloop Pipeline Products & Ongoing Clinical Trials Overview 36
  • 5.15 Giner Inc Company Overview 39
    • 5.15.1 Giner Inc Pipeline Products & Ongoing Clinical Trials Overview 39
  • 5.16 Imperial College London Company Overview 40
    • 5.16.1 Imperial College London Pipeline Products & Ongoing Clinical Trials Overview 40
  • 5.17 Inreda Diabetic BV Company Overview 41
    • 5.17.1 Inreda Diabetic BV Pipeline Products & Ongoing Clinical Trials Overview 41
  • 5.18 Insulet Corp Company Overview 42
    • 5.18.1 Insulet Corp Pipeline Products & Ongoing Clinical Trials Overview 42
  • 5.19 Kencak LLC Company Overview 43
    • 5.19.1 Kencak LLC Pipeline Products & Ongoing Clinical Trials Overview 43
  • 5.20 Medtronic plc Company Overview 44
    • 5.20.1 Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 44
  • 5.21 Miromatrix Medical Inc Company Overview 52
    • 5.21.1 Miromatrix Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 52
  • 5.22 Nikkiso Co., Ltd. Company Overview 53
    • 5.22.1 Nikkiso Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 53
  • 5.23 Pacific Diabetes Technologies, Inc. Company Overview 54
    • 5.23.1 Pacific Diabetes Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 54
  • 5.24 Pancreum, LLC Company Overview 55
    • 5.24.1 Pancreum, LLC Pipeline Products & Ongoing Clinical Trials Overview 55
  • 5.25 PharmaCyte Biotech Inc Company Overview 56
    • 5.25.1 PharmaCyte Biotech Inc Pipeline Products & Ongoing Clinical Trials Overview 56
  • 5.26 Polytechnic University of Valencia Company Overview 57
    • 5.26.1 Polytechnic University of Valencia Pipeline Products & Ongoing Clinical Trials Overview 57
  • 5.27 Rensselaer Polytechnic Institute Company Overview 58
    • 5.27.1 Rensselaer Polytechnic Institute Pipeline Products & Ongoing Clinical Trials Overview 58
  • 5.28 Schneider Children's Medical Center of Israel Company Overview 59
    • 5.28.1 Schneider Children's Medical Center of Israel Pipeline Products & Ongoing Clinical Trials Overview 59
  • 5.29 Senseonics Holdings, Inc. Company Overview 60
    • 5.29.1 Senseonics Holdings, Inc. Pipeline Products & Ongoing Clinical Trials Overview 60
  • 5.30 TecMed, Inc. Company Overview 63
    • 5.30.1 TecMed, Inc. Pipeline Products & Ongoing Clinical Trials Overview 63
  • 5.31 The University of Newcastle Company Overview 64
    • 5.31.1 The University of Newcastle Pipeline Products & Ongoing Clinical Trials Overview 64
  • 5.32 TypeZero Technologies LLC Company Overview 65
    • 5.32.1 TypeZero Technologies LLC Pipeline Products & Ongoing Clinical Trials Overview 65
  • 5.33 Ultradian Diagnostics LLC Company Overview 68
    • 5.33.1 Ultradian Diagnostics LLC Pipeline Products & Ongoing Clinical Trials Overview 68
  • 5.34 Universidad Autonoma de Madrid Company Overview 69
    • 5.34.1 Universidad Autonoma de Madrid Pipeline Products & Ongoing Clinical Trials Overview 69
  • 5.35 University of California San Francisco Company Overview 70
    • 5.35.1 University of California San Francisco Pipeline Products & Ongoing Clinical Trials Overview 70
  • 5.36 University of California Santa Barbara Company Overview 71
    • 5.36.1 University of California Santa Barbara Pipeline Products & Ongoing Clinical Trials Overview 71
  • 5.37 University of Cambridge Company Overview 73
    • 5.37.1 University of Cambridge Pipeline Products & Ongoing Clinical Trials Overview 73
  • 5.38 University of Florida Company Overview 78
    • 5.38.1 University of Florida Pipeline Products & Ongoing Clinical Trials Overview 78
  • 5.39 XERIS Pharmaceuticals Inc Company Overview 79
    • 5.39.1 XERIS Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 79

6 Artificial Pancreas - Recent Developments 80

  • 6.1 Jul 26, 2017: PharmaCyte Biotech Appoints Dr. Linda S. Sher as Chief Medical Officer 80
  • 6.2 Jul 10, 2017: PharmaCyte Biotech Appoints Dr. Michael M. Abecassis to Board of Directors 81
  • 6.3 Jun 26, 2017: Medtronic Announces Outcomes-Based Agreement with Aetna for Type 1 and Type 2 Diabetes Patients 82
  • 6.4 Jun 22, 2017: Phase 2a trial results support development of dasiglucagon in the iLet pump system for type 1 diabetes 82
  • 6.5 Jun 12, 2017: Insulet Presents Positive Omnipod Horizon Hybrid Closed-Loop Study Results in Children 84
  • 6.6 Jun 07, 2017: Medtronic Initiates U.S. Launch of World's First Hybrid Closed Loop System for Type 1 Diabetes 84
  • 6.7 May 30, 2017: Insulet Appoints Bret Christensen as Chief Commercial Officer 86
  • 6.8 May 25, 2017: Medtronic Reports Fourth Quarter and Fiscal Year 2017 Financial Results 86
  • 6.9 May 08, 2017: Insulet Reports First Quarter 2017 Financial Results 89
  • 6.10 May 02, 2017: PharmaCyte Biotech Appoints Thomas Yuen to Board of Directors 90
  • 6.11 Apr 28, 2017: Artificial pancreas benefits young children, trial shows 91
  • 6.12 Apr 20, 2017: Cellnovo announces that Diabeloop is launching a CE marking Registration Study on Artificial Pancreas with Cellnovo pump 91
  • 6.13 Apr 19, 2017: PharmaCyte Biotech Receives the 2017 "Pipelines of Promise" Award from BIO International 92
  • 6.14 Apr 03, 2017: PharmaCyte Biotech Appoints Dr. Mark Rabe Director of Cannabis Program Development 93
  • 6.15 Mar 30, 2017: ConvaTec Expands Unomedical Manufacturing Technology Partnership with Medtronic Diabetes to Meet Growing Demand 94
  • 6.16 Mar 13, 2017: PharmaCyte Biotech Names Dr. Leonard Makowka as Senior Strategic Advisor 94
  • 6.17 Mar 06, 2017: Important Update On Minimed 670G Availability And The Priority Access Program 95
  • 6.18 Feb 27, 2017: Insulet Reports Fourth Quarter and Full Year 2016 Financial Results 96
  • 6.19 Feb 21, 2017: Medtronic Reports Third Quarter Financial Results 98
  • 6.20 Feb 17, 2017: Insulet Presents Strong Omnipod Horizon Hybrid Closed-Loop Study Results at ATTD in Paris 101
  • 6.21 Feb 13, 2017: National Institutes of Health Funds Schneider Children's Medical Center and International Diabetes Center Closed-Loop System Research 102
  • 6.22 Feb 06, 2017: Medtronic Awarded U.S. Department of Veterans Affairs National Contracts for Home Telehealth Technologies, with Three Other Vendors 103
  • 6.23 Jan 09, 2017: Xeris Pharmaceuticals Announces Appointment of Paul R. Edick as President and CEO 103
  • 6.24 Jan 05, 2017: Cellnovo and Diabeloop Update on Artificial Pancreas 104
  • 6.25 Dec 19, 2016: Bionic pancreas system successfully controls blood sugar without risk of hypoglycemia 105
  • 6.26 Nov 22, 2016: Medtronic Reports Second Quarter Financial Results 106
  • 6.27 Nov 16, 2016: Medtronic Releases FY16 Integrated Performance Report 109
  • 6.28 Nov 15, 2016: CEVA to work with Medtronic for distribution facility construction 110
  • 6.29 Nov 03, 2016: Insulet Reports Third Quarter 2016 Financial Results 111
  • 6.30 Oct 19, 2016: Insulet Announces Board and Management Changes 112
  • 6.31 Sep 28, 2016: FDA approves first automated insulin delivery device for type 1 diabetes 112
  • 6.32 Sep 15, 2016: The Journal of the American Medical Association Publishes Medtronic's Hybrid Closed Loop System Pivotal Trial Results 113
  • 6.33 Sep 15, 2016: Medtronic Names Mark Ploof Senior Vice President of Global Operations and Business Services 114
  • 6.34 Sep 13, 2016: Insulet Enrolls First Patients in Clinical Trial for its Omnipod Artificial Pancreas System 115
  • 6.35 Sep 06, 2016: Insulet to Establish Highly-Automated Manufacturing Operation in the United States 116
  • 6.36 Sep 06, 2016: Insulet Announces Executive Appointments 116
  • 6.37 Sep 05, 2016: Artificial pancreas trial in young children with diabetes receives €4.6millon grant from European Commission 117
  • 6.38 Aug 25, 2016: Medtronic Reports First Quarter Financial Results 118

7 Appendix 121

  • 7.1 Methodology 121
  • 7.2 About GlobalData 124
  • 7.3 Contact Us 124
  • 7.4 Disclaimer 124

List of Tables

1.1 List of Tables

  • Table 1: Artificial Pancreas - Pipeline Products by Stage of Development 10
  • Table 2: Artificial Pancreas - Pipeline Products by Territory 11
  • Table 3: Artificial Pancreas - Pipeline Products by Regulatory Path 12
  • Table 4: Artificial Pancreas - Pipeline Products by Estimated Approval Date 13
  • Table 5: Artificial Pancreas - Ongoing Clinical Trials 14
  • Table 6: Artificial Pancreas Companies - Pipeline Products by Stage of Development 15
  • Table 7: Artificial Pancreas - Pipeline Products by Stage of Development 17
  • Table 8: Admetsys Corporation Pipeline Products & Ongoing Clinical Trials Overview 19
  • Table 9: Admetsys Smart Pancreas - Product Status 19
  • Table 10: Admetsys Smart Pancreas - Product Description 19
  • Table 11: Advanced Biosensors-Ohio, Llc Pipeline Products & Ongoing Clinical Trials Overview 20
  • Table 12: Artificial Pancreas - Product Status 20
  • Table 13: Artificial Pancreas - Product Description 20
  • Table 14: Animas Corp Pipeline Products & Ongoing Clinical Trials Overview 21
  • Table 15: Hypoglycemia-Hyperglycemia Minimizer System - Product Status 21
  • Table 16: Hypoglycemia-Hyperglycemia Minimizer System - Product Description 21
  • Table 17: Beta Bionics Inc Pipeline Products & Ongoing Clinical Trials Overview 22
  • Table 18: iLet - Product Status 22
  • Table 19: iLet - Product Description 22
  • Table 20: Beta Bionics Inc - Ongoing Clinical Trials Overview 23
  • Table 21: iLet - A Multicenter Study of Outpatient Automated Blood Glucose Control with a Bihormonal Bionic Pancreas 24
  • Table 22: iLet - Closed-loop Glucagon Administration for the Automated Prevention and Treatment of Hypoglycemia 24
  • Table 23: Beta-O2 Technologies Ltd Pipeline Products & Ongoing Clinical Trials Overview 25
  • Table 24: BAir Bio-artificial Pancreas - Product Status 25
  • Table 25: BAir Bio-artificial Pancreas - Product Description 25
  • Table 26: Beta-O2 Technologies Ltd - Ongoing Clinical Trials Overview 26
  • Table 27: BAir Bio-artificial Pancreas - An Open Label, Pilot Investigation, to Assess the Safety and Efficacy of Transplantation of Macro-encapsulated Human Islets within the Bioartificial Pancreas Beta-Air in Patients with Type 1 Diabetes Mellitus 27
  • Table 28: Bigfoot Biomedical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 28
  • Table 29: Smartloop Automated Insulin Delivery System - Product Status 28
  • Table 30: Smartloop Automated Insulin Delivery System - Product Description 28
  • Table 31: BioTex Inc Pipeline Products & Ongoing Clinical Trials Overview 29
  • Table 32: Artificial Pancreas - Product Status 29
  • Table 33: Artificial Pancreas - Product Description 29
  • Table 34: Cerco Medical LLC Pipeline Products & Ongoing Clinical Trials Overview 30
  • Table 35: Islet Sheet - Product Status 30
  • Table 36: Islet Sheet - Product Description 30
  • Table 37: Converge Biotech, Inc. Pipeline Products & Ongoing Clinical Trials Overview 31
  • Table 38: Bioartificial Pancreas System - Product Status 31
  • Table 39: Bioartificial Pancreas System - Product Description 31
  • Table 40: Covalor Medical, LLC Pipeline Products & Ongoing Clinical Trials Overview 32
  • Table 41: Artificial Pancreas - Product Status 32
  • Table 42: Artificial Pancreas - Product Description 32
  • Table 43: De Montfort University Pipeline Products & Ongoing Clinical Trials Overview 33
  • Table 44: InSmart Artificial Pancreas - Product Status 33
  • Table 45: InSmart Artificial Pancreas - Product Description 33
  • Table 46: Debiotech SA Pipeline Products & Ongoing Clinical Trials Overview 34
  • Table 47: Next Generation Artificial Pancreas - Product Status 34
  • Table 48: Next Generation Artificial Pancreas - Product Description 34
  • Table 49: Defymed Inc Pipeline Products & Ongoing Clinical Trials Overview 35
  • Table 50: MAILPAN - Product Status 35
  • Table 51: MAILPAN - Product Description 35
  • Table 52: Diabeloop Pipeline Products & Ongoing Clinical Trials Overview 36
  • Table 53: Diabeloop Artificial Pancreas - Product Status 36
  • Table 54: Diabeloop Artificial Pancreas - Product Description 36
  • Table 55: Diabeloop - Ongoing Clinical Trials Overview 37
  • Table 56: Diabeloop Artificial Pancreas - Crossover Evaluation of the Safety and the Efficacy of Artificial Pancreas Diabeloop for Three Months at Home in Comparison with Conventional Treatment by External Insulin Pump in Patients with Type 1 Diabetes 38
  • Table 57: Giner Inc Pipeline Products & Ongoing Clinical Trials Overview 39
  • Table 58: BAPIOS System - Product Status 39
  • Table 59: BAPIOS System - Product Description 39
  • Table 60: Imperial College London Pipeline Products & Ongoing Clinical Trials Overview 40
  • Table 61: Bio-inspired Artificial Pancreas - Product Status 40
  • Table 62: Bio-inspired Artificial Pancreas - Product Description 40
  • Table 63: Inreda Diabetic BV Pipeline Products & Ongoing Clinical Trials Overview 41
  • Table 64: Bi-Hormonal Artificial Pancreas - Product Status 41
  • Table 65: Bi-Hormonal Artificial Pancreas - Product Description 41
  • Table 66: Insulet Corp Pipeline Products & Ongoing Clinical Trials Overview 42
  • Table 67: Omnipod Horizon Hybrid Closed Loop System - Product Status 42
  • Table 68: Omnipod Horizon Hybrid Closed Loop System - Product Description 42
  • Table 69: Kencak LLC Pipeline Products & Ongoing Clinical Trials Overview 43
  • Table 70: BioArtificial Pancreas - Product Status 43
  • Table 71: BioArtificial Pancreas - Product Description 43
  • Table 72: Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 44
  • Table 73: MiniMed 640G System - Product Status 44
  • Table 74: MiniMed 640G System - Product Description 45
  • Table 75: MiniMed 670G - Product Status 45
  • Table 76: MiniMed 670G - Product Description 45
  • Table 77: Third-Generation Artificial Pancreas System - Product Status 46
  • Table 78: Third-Generation Artificial Pancreas System - Product Description 46
  • Table 79: Medtronic plc - Ongoing Clinical Trials Overview 47
  • Table 80: MiniMed 670G - A Crossover Study Comparing Two Automated Insulin Delivery System Algorithms (PID vs. PID + Fuzzy Logic) in Adolescents and Young Adults with Type 1 Diabetes 48
  • Table 81: MiniMed 670G - Clinical Startup of the 670G Closed Loop Insulin Delivery System 48
  • Table 82: MiniMed 670G - Effect of Hybrid Closed-loop Insulin Delivery on Glucose Counterregulation in Long Standing Type 1 Diabetes: A Proof of Concept, Mechanistic, Single-arm Clinical Trial 48
  • Table 83: MiniMed 670G - Feasibility Study to Evaluate the Hybrid-Logic Closed Loop System in Type 1 Diabetes -Single-arm, Single-center, in Clinic Study-The DREAMED Trail 49
  • Table 84: MiniMed 670G - Multi-center, Randomized, Adaptive, Controlled Trial in Adult and Pediatric Patients with Type 1 Diabetes Using Hybrid Closed Loop System at Home 49
  • Table 85: MiniMed 670G - Safety Evaluation of the Hybrid Closed Loop (HCL) System in Pediatric Subjects with Type 1 Diabetes 49
  • Table 86: MiniMed 640G System - An Open-label, Multi-center, Randomized, 2-period Cross-over Study to Assess the Efficacy and Safety of Closed Loop Insulin Delivery Using Diluted Insulin in Comparison with Closed Loop with Non-diluted Insulin Over 21 Days in Children with Type 1 Diabetes Aged 1 to 7 Years in the Home Setting 50
  • Table 87: MiniMed 640G System - An Open-label, Multicenter, Randomized, Single-period, Parallel Design Study to Assess the Effect of Closed Loop Insulin Delivery from Onset of Type 1 Diabetes in Youth on Residual Beta Cell Function Compared to Standard Insulin Therapy 50
  • Table 88: MiniMed 640G System - Evaluation of Two Different Glucose Monitoring Treatments and Their Impact on Time in Target, Sleep and Quality of Life in Children with Type 1 Diabetes and Primary Caregivers 51
  • Table 89: MiniMed 640G System - Study of MiniMed 640G Insulin Pump With SmartGuard in Prevention of Low Glucose Events in Adults With Type 1 Diabetes 51
  • Table 90: MiniMed 640G System - Study of Minimed 640G Insulin Pump with SmartGuard in Prevention of Low Glucose Events in Adults with Type 1 Diabetes at Risk of Severe Hypoglycemia 51
  • Table 91: Miromatrix Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 52
  • Table 92: Miro Pancreas - Product Status 52
  • Table 93: Miro Pancreas - Product Description 52
  • Table 94: Nikkiso Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 53
  • Table 95: Artificial Pancreas - Product Status 53
  • Table 96: Artificial Pancreas - Product Description 53
  • Table 97: Pacific Diabetes Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 54
  • Table 98: Artificial Endocrine Pancreas - Product Status 54
  • Table 99: Artificial Endocrine Pancreas - Product Description 54
  • Table 100: Pancreum, LLC Pipeline Products & Ongoing Clinical Trials Overview 55
  • Table 101: Genesis Artificial Pancreas - Product Status 55
  • Table 102: Genesis Artificial Pancreas - Product Description 55
  • Table 103: PharmaCyte Biotech Inc Pipeline Products & Ongoing Clinical Trials Overview 56
  • Table 104: Bio-Artificial Pancreas - Product Status 56
  • Table 105: Bio-Artificial Pancreas - Product Description 56
  • Table 106: Polytechnic University of Valencia Pipeline Products & Ongoing Clinical Trials Overview 57
  • Table 107: ClosedLoop 4Meal Control - Product Status 57
  • Table 108: ClosedLoop 4Meal Control - Product Description 57
  • Table 109: Rensselaer Polytechnic Institute Pipeline Products & Ongoing Clinical Trials Overview 58
  • Table 110: Closed-Loop Artificial Pancreas System - Product Status 58
  • Table 111: Closed-Loop Artificial Pancreas System - Product Description 58
  • Table 112: Schneider Children's Medical Center of Israel Pipeline Products & Ongoing Clinical Trials Overview 59
  • Table 113: MD-Logic Artificial Pancreas - Product Status 59
  • Table 114: MD-Logic Artificial Pancreas - Product Description 59
  • Table 115: Senseonics Holdings, Inc. Pipeline Products & Ongoing Clinical Trials Overview 60
  • Table 116: Eversense CGM System Integrated With inControl And Accu-Chek Insight Insulin Pump - Product Status 60
  • Table 117: Eversense CGM System Integrated With inControl And Accu-Chek Insight Insulin Pump - Product Description 60
  • Table 118: Senseonics Holdings, Inc. - Ongoing Clinical Trials Overview 61
  • Table 119: Eversense CGM System Integrated With inControl And Accu-Chek Insight Insulin Pump - Clinical Acceptance of the Artificial Pancreas: The International Diabetes Closed Loop (iDCL) Trial Research Site Training Protocol 62
  • Table 120: Eversense CGM System Integrated With inControl And Accu-Chek Insight Insulin Pump - Clinical Acceptance of the Artificial Pancreas: The International Diabetes Closed Loop (iDCL) Trial: A Randomized Clinical Trial to Assess the Efficacy of Adjunctive Closed Loop Control Versus Sensor-augmented Pump Therapy in the Management of Type 1 Diabetes 62
  • Table 121: TecMed, Inc. Pipeline Products & Ongoing Clinical Trials Overview 63
  • Table 122: TecMed Artificial Pancreas - Product Status 63
  • Table 123: TecMed Artificial Pancreas - Product Description 63
  • Table 124: The University of Newcastle Pipeline Products & Ongoing Clinical Trials Overview 64
  • Table 125: Closed Glucose-Sensing Insulin-Delivery System - Product Status 64
  • Table 126: Closed Glucose-Sensing Insulin-Delivery System - Product Description 64
  • Table 127: TypeZero Technologies LLC Pipeline Products & Ongoing Clinical Trials Overview 65
  • Table 128: inControl - Product Status 65
  • Table 129: inControl - Product Description 65
  • Table 130: TypeZero Technologies LLC - Ongoing Clinical Trials Overview 66
  • Table 131: inControl - Clinical Acceptance of the Artificial Pancreas: The International Diabetes Closed Loop (iDCL) Trial Research Site Training Protocol 67
  • Table 132: inControl - Clinical Acceptance of the Artificial Pancreas: The International Diabetes Closed Loop (iDCL) Trial: A Randomized Clinical Trial to Assess the Efficacy of Adjunctive Closed Loop Control Versus Sensor-augmented Pump Therapy in the Management of Type 1 Diabetes 67
  • Table 133: inControl - Examination of New Control Algorithm of inControl AP 67
  • Table 134: Ultradian Diagnostics LLC Pipeline Products & Ongoing Clinical Trials Overview 68
  • Table 135: Artificial Pancreas - Product Status 68
  • Table 136: Artificial Pancreas - Product Description 68
  • Table 137: Universidad Autonoma de Madrid Pipeline Products & Ongoing Clinical Trials Overview 69
  • Table 138: Predictive Rule-Based Algorithm - Product Status 69
  • Table 139: Predictive Rule-Based Algorithm - Product Description 69
  • Table 140: University of California San Francisco Pipeline Products & Ongoing Clinical Trials Overview 70
  • Table 141: Bioartificial Pancreas - Product Status 70
  • Table 142: Bioartificial Pancreas - Product Description 70
  • Table 143: University of California Santa Barbara Pipeline Products & Ongoing Clinical Trials Overview 71
  • Table 144: Closed-Loop Artificial Pancreas - Product Status 71
  • Table 145: Closed-Loop Artificial Pancreas - Product Description 71
  • Table 146: Pediatric Artificial Pancreas - Product Status 72
  • Table 147: Pediatric Artificial Pancreas - Product Description 72
  • Table 148: University of Cambridge Pipeline Products & Ongoing Clinical Trials Overview 73
  • Table 149: Artificial Pancreas - Product Status 73
  • Table 150: Artificial Pancreas - Product Description 73
  • Table 151: Florence D2A System - Product Status 74
  • Table 152: Florence D2A System - Product Description 74
  • Table 153: University of Cambridge - Ongoing Clinical Trials Overview 75
  • Table 154: Florence D2A System - Closing the Loop in Adults with Type 1 Diabetes and HbA1C Less than 7.5% Under Free Living Conditions 76
  • Table 155: Artificial Pancreas - An Open-label, Multi-center, Randomized, 2-period Cross-over Study to Assess the Efficacy and Safety of Closed Loop Insulin Delivery Using Diluted Insulin in Comparison with Closed Loop with Non-diluted Insulin Over 21 Days in Children with Type 1 Diabetes Aged 1 to 7 Years in the Home Setting 77
  • Table 156: University of Florida Pipeline Products & Ongoing Clinical Trials Overview 78
  • Table 157: Bioartificial Pancreas - Type 1 Diabetes - Product Status 78
  • Table 158: Bioartificial Pancreas - Type 1 Diabetes - Product Description 78
  • Table 159: XERIS Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 79
  • Table 160: G-Pump - BP - Product Status 79
  • Table 161: G-Pump - BP - Product Description 79
  • Table 162: Glossary 123

List of Figures

1.2 List of Figures

  • Figure 1: Artificial Pancreas - Pipeline Products by Stage of Development 10
  • Figure 2: Artificial Pancreas - Pipeline Products by Territory 11
  • Figure 3: Artificial Pancreas - Pipeline Products by Regulatory Path 12
  • Figure 4: Artificial Pancreas - Pipeline Products by Estimated Approval Date 13
  • Figure 5: Artificial Pancreas - Ongoing Clinical Trials 14
Back to Top